cefamandole and Genital-Diseases--Female

Ten patients suffering from genital organ infections, urinary tract infections and symptomless bacteriuria were treated with cefamandole (CMD). CMD was administered intravenously and drip infusion at a dosage of 4.0 g/day for 4 approximately 10 days. Clinical results obtained were as follows: Of 6 patients with genital organ infections, excellent responses were seen in 2 patients, good responses in 4 patients. Of 3 patients with urinary tract infections, excellent responses were seen in 2 patients, and good response in 1 patient. The overall efficacy rate was 100%. In the cases of urinary tract infections and symptomless bacteriuria, 3 strains of E. coli and 1 strain of Streptococcus faecalis disappeared. On the other hand, in genital organ infections, we had no bacterial findings. No significant reaction was observed in clinical laboratory findings of hemogram or in test on renal and hepatic functions, except slight transient leukopenia observed in 1 patient.

Topics: Adult; Aged; Bacterial Infections; Cefamandole; Cephalosporins; Clinical Trials as Topic; Female; Genital Diseases, Female; Humans; Middle Aged; Urinary Tract Infections

1) Tissue concentrations of cefamandole (CMD) one hour after the end of 2 g/30 approximately 60 minutes drip infusion were 7.3 approximately 13.1 microgram/g in uterus, ovary and oviduct. These concentrations were higher than MICs of 70 approximately 100% of causative organisms, including Staphylococcus aureus, Escherichia coli, Klebsiella, Proteus mirabilis, Enterobacter and Citrobacter, isolated from the infections in the field of obstetrics and gynecology. 2) CMD was administered to 14 patients with moderate infections in the field of obstetrics and gynecology at a daily dose of 4 g for 5 approximately 7 days. The overall clinical efficacy obtained was as follows; excellent in 7 cases (50%), good in 3 cases (21%) and poor in 4 cases (29%). 3) Antimicrobial activity of CMD against causative organisms resembled that of CEZ. 4) No adverse effects and abnormal laboratory findings were observed. From the above, we considered that CMD was an effective and safe antibiotic against infections in the field of obstetrics and gynecology.

Topics: Adult; Aged; Bacterial Infections; Cefamandole; Cephalosporins; Clinical Trials as Topic; Female; Genital Diseases, Female; Genitalia, Female; Humans; Middle Aged

Cefamandole nafate has been shown to have good in vitro activity against a wide spectrum of aerobic and anaerobic pathogens frequently isolated from women with obstetrical and gynecological infections. One hundred and twenty seven women with these infections were treated with cefamandole: 78 had post-cesarean section metritis; 24 acute pelvic inflammatory disease; 18 post-hysterectomy cuff cellulitis/abscess; and 7 had vulvar or abdominal wound abscesses. All but 13% of these women had either polymicrobial aerobic/anaerobic bacterial infections, or had an anaerobic infection alone. Of these 127 women, 116 responded to cefamandole administration alone, and in the other 11 chloramphenicol was added. Of these 11, surgical therapy was necessary to eradicate infection in six women. Phlebitis, mild to severe, was demonstrated in 14% of the women and responded to conservative measures. Of 402 bacterial isolates from these women, 94% were sensitive to cefamandole at 32 microgram/ml, an easily achievable serum level. Anaerobic streptococci were the most common isolate and 94% of these organisms were sensitive at 32 microgram/ml. Of the 43 Bacteroides species isolated, 90% were susceptible at 32 microgram/ml; 84% of Bacteroides fragilis were susceptible ast this concentration. Data now presented indicate that cefamandole given alone is safe and effective for treatment of women with polymicrobial mixed aerobic/anaerobic pelvic infections and approximately 5% will require surgical therapy for eradication of these infections.

Topics: Aerobiosis; Anaerobiosis; Bacteria; Bacterial Infections; Bacteroides; Cefamandole; Cephalosporins; Cesarean Section; Chloramphenicol; Clinical Trials as Topic; Female; Genital Diseases, Female; Humans; Phlebitis; Postoperative Complications; Pregnancy; Puerperal Disorders

Topics: Adolescent; Adult; Bacterial Infections; Cefamandole; Cephalosporins; Cesarean Section; Female; Genital Diseases, Female; Humans; Middle Aged; Postoperative Complications

Cefamandole nafate is a derivative of 7-aminocephalosporanic acid which has been shown to have good in vitro activity against aerobes traditionally susceptible to cephalosporins as well as many anaerobes, including B. fragilis. One hundred women with obstetric or gynecologic infections completed treatment with cefamandole: 53 had post-cesarean section infections: 24, acute pelvic inflammatory disease: 16, posthysterectomy cuff cellulitis/abscess; and seven, vulvar or abdominal wound abscess. Almost 90% of these women had either polymicrobial aerobic/anaerobic bacterial infections or an anaerobic infection alone. Ninety women responded to cefamandole alone; in 10 cases chloramphenicol was added, but in addition five of these women required surgical therapy for eradication of infection. Mild to severe phlebitis at the infusion site that responded to conservative therapy was demonstrated in 14 women. Of 312 bacterial isolates from these women, 89% were sensitive to cefamandole at 32 microgram/ml, an easily achievable serum level; 93% of anaerobic streptococci, the most common isolates, were sensitive at 32 microgram/ml. Also, 90% of all Bacteroides species were susceptible at 32 microgram/ml; 82% of B. fragilis were susceptible at this concentration. These data indicate that cefamandole is safe and effective for treatment of women with polymicrobial pelvic infections but that approximately 5% of these women will require surgical exploration in addition to antimicrobial administration.

Topics: Abscess; Acute Disease; Bacterial Infections; Bacteroides Infections; Cefamandole; Cellulitis; Cephalosporins; Cesarean Section; Clostridium Infections; Endometritis; Enterobacteriaceae Infections; Female; Genital Diseases, Female; Humans; Hysterectomy; Peptococcus; Peptostreptococcus; Peritonitis; Pregnancy; Streptococcal Infections; Surgical Wound Infection; Vulvitis